Blog & News

9th SPAEN Annual Conference 1-3 Feb 2019 in Athens: Registration now open!

Jan 15, 2017 |

Quality of Life for Sarcoma Patients

Jan 15, 2017 |

ASCO 2017: GIST and Sarcoma Reports available

Jan 15, 2017 |

  The Annual Meeting of the American Society of Clinical Oncology is one of the most important meetings of healthcare professionals in the world. We are therefore delighted to provide you with a comprehensive report about the ASCO 2017 medical highlights in…

International Top 10 recommendations for newly diagnosed GIST patients

Jan 15, 2017 |

For national GIST Patient Support and Advocacy groups: Please translate this list into your national language and provide the document for GIST-Patients on your website. Thank you very much! 1. Gastrointestinal stromal tumours (GISTs) belong to the group of sarcomas; they are…

International Top 10 Recommendations For Newly Diagnosed GIST Patients

Jan 15, 2017 |

For national GIST Patient Support and Advocacy groups: Please translate this list into your national language and provide the document for GIST-Patients on your website. Thank you very much! International “Top-10-Recommendations” for newly diagnosed GIST-Patients. 1. Gastrointestinal stromal tumours (GISTs) belong to…

Early Involvement: Clinical Studies From A Patient Perspective

Jan 15, 2017 |

Clinical studies are an essential step in the development of novel treatment methods for cancer and other diseases. They show researchers what works for the welfare of patients and what does not. In addition to safety and effectiveness they also determine whether…

Find International Sarcoma Studies In Our Registry

Jan 15, 2017 |

Launch of a Sarcoma Patientgroup in India: SPANDAN

Jan 15, 2017 |

Find Out More About SPAEN National Member Groups

Jan 15, 2017 |

Backgrounder Generics

Dec 21, 2016 |

Generics have been part of the prescriptions in cancer therapy for quite some time now. And the numbers grow: According to recent figures mentioned in Cancer Work in a total global oncology drugs market approaching $100 billion, revenues from generics are growing…